![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing... Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Show more
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. βWe...
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.93 | 17.3717371737 | 11.11 | 14 | 11.11 | 24494 | 13.26048242 | CS |
4 | 1.4 | 12.0274914089 | 11.64 | 14 | 9.98 | 16954 | 11.90953675 | CS |
12 | -1.21 | -8.49122807018 | 14.25 | 20.85 | 8.9174 | 83067 | 14.41526949 | CS |
26 | -0.52 | -3.83480825959 | 13.56 | 34.46 | 3.9501 | 775267 | 15.18359852 | CS |
52 | -169.888 | -92.871512289 | 182.928 | 588 | 3.9501 | 23393183 | 32.85863523 | CS |
156 | -675.76 | -98.1068524971 | 688.8 | 1711.2 | 3.9501 | 8438400 | 39.32856323 | CS |
260 | -675.76 | -98.1068524971 | 688.8 | 1711.2 | 3.9501 | 8438400 | 39.32856323 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions